## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent A	Application of:	)	Group Art Unit:	To Be Assigned
Nunomura		)	Examiner:	To Be Assigned
Serial No.: T	To be assigned	)	Atty. Docket No.:	GP104-03.CN1
	Application of: /620,958 filed July 21, 2000	) ) )		
Filed: F	Herewith	)		
	POLYNUCLEOTIDE AMPLIFICATION METHOD	) ) )		

## INFORMATION DISCLOSURE STATEMENT UNDER C.F.R. § 1.97(b)

Box PATENT APPLICATION Commissioner for Patents Washington, D.C. 20231

## Dear Sir:

Applicant brings to the Examiner's attention the references listed on the attached form PTO-1449 (submitted in duplicate). Each of these references was previously cited during the prosecution of parent application Serial No. 09/620,958. Accordingly, copies of these references are not enclosed.

This Information Disclosure Statement is being submitted under 37 CFR § 1.97(b) within three months of the filing date of the instant application.

Applicant respectfully requests that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO-1449 with the Examiner's initials or other appropriate marks.

Continuation of Serial No. 09/620,958 Atty. Docket No. GP104-03.CN1

IDS

No fee is believed due in connection with this Information Disclosure Statement. If Applicant is mistaken, please charge the amount due to Deposit Account No. 07-0835.

## Certificate of Mailing by Express Mail

I hereby certify that this correspondence (along with any referred to as being attached) is being deposited on the date indicated below with the U.S. Postal Service as express mail (Express Mail No. EL612500552US) addressed to Box PATENT APPLICATION, Commissioner for Patents, Washington, D.C. 20231.

Respectfully Submitted,

Date: August 30, 2001

By: Michael J. Gilly

Registration No. 42,579

Agent for Applicant

GEN-PROBE INCORPORATED

Patent Department 10210 Genetic Center Drive San Diego, California 92121

PH: (858) 410-8657 FAX: (858) 410-8928

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.				
FORM F10-1443	PATENT AND TRADEMARK OFFICE	GP104-03.CN1	To be assigned				
		APPLICANT					
INFORMATI	ON DISCLOSURE STATEMENT	Nunomura, K.					
	BY APPLICANT	FILING DATE	GROUP				
(USE SEVE	RAL SHEETS IF NECESSARY)	August 30, 2001	To Be Assigned				
			~-D-				

	U.S. PATENT DOCUMENTS												
EXAMINER INITIAL			DOC	UME	ENT	NUM	BER		DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
		4	6	8	3	1	9	5	07/28/87	Mullis et al.	435	6	
		5	2	1	9	7	2	7	06/15/93	Wang et al.	435	6	
		5	2	8	3	1	7	4	02/01/94	Arnold, Jr. et al.	435	6	
		5	3	9	9	4	9	1	03/21/95	Kacian et al.	435	91.21	
		5	7	0_	5	3	6_	5	01/06/98	Ryder et al.	435	91.1	
		5	7_	1	0	0	2	9	01/20/98	Ryder et al.	435	91.1	

	FOREIGN PATENT DOCUMENTS													
EXAMINER	DOCUMENT NUMBER					NUM	BER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL													YES	NO
		9	1	0_	2	8	1	8	03/07/91	PCT				
		9	3	0	2_	2	1	5	02/04/93	PCT				
		9	5_	0	3	4	3	0_	02/02/95	PCT				
		0	3	2	0	3	0	8	06/14/89	EP				
		0	4	9	7	2	7	2	08/05/92	EP				
		0	5_	2	5	8	8	2_	02/03/93	EP				
		0	5	8	7	2	6	6	03/16/94	EP				
		0	5	8	7	2	9	8	03/16/94	EP				
		0	6	2	3	6	8	2_	11/09/94	EP				

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
		Chelly et al., :Transcription of the dystrophin gene in human muscle and non-muscle tissues", Nature, 333:858-860 (June 1988)
		Persing, "In Vitro Nucleic Acid Amplification Techniques", Diagnostic Molecular Microbiology - Principles and Applications", (Persing et al., eds.) Part 1, Chpt. 3, citing 2 sections: Quantitative PCR and Transcription-Based Amplification Systems: TAS and 3SR (incl. Figure 4.), pgs. 65-67 (1993)*
	С	van Gemen et al., "A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes", J. Virol. Meth., $49:157-168$ (1994)*
	D	Natarajan V. et al., "An Internally Controlled Virion PCR for the Measurement of HIV-1 RNA in Plasma", PCR Methods and Applications, Vol. 3, pp. 346-350 (June 1994)

\*The year of publication is sufficiently earlier than the effective U.S. Filing date so that the particular month of publication is not in issue.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE CO	CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH DPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.